What is OABI's current stock price?

OABI (OmniAb, Inc.) is currently trading at $2.65 with a market cap of $315.6M.

What sector is OmniAb, Inc. in?

OmniAb, Inc. (OABI) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is OABI a good stock to buy?

Analysts have a Buy consensus on OABI with a price target of $4.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

OABI OmniAb, Inc.

Healthcare

$2.65+3.92%ClosedMarket Cap: $315.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.29

P/S

10.92

EV/EBITDA

-8.72

DCF Value

$-0.43

FCF Yield

-8.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

35.5%

Operating Margin

-200.3%

Net Margin

-187.7%

ROE

-20.3%

ROA

-18.5%

ROIC

-20.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$14.4M	$-7.7M	$—
Q4 null	$8.4M	$-14.2M	$—
FY null	$18.7M	$-64.8M	$—
Q3 null	$2.2M	$-16.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$4.00

Target (Median)

$4.00

Target Range

$4.00 - $4.00

0 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

RBC CapitalOutperform

2025-08-07

Trading Activity

Insider Trades

View All

Gotwals Philip Jdirector

SellTue Apr 21

Crouse Steven C.director

SellTue Apr 21

GUSTAFSON KURT Aofficer: Executive VP, Finance and CFO

SellTue Apr 07

GUSTAFSON KURT Aofficer: Executive VP, Finance and CFO

SellTue Apr 07

FOEHR MATTHEW Wdirector, officer: President and CEO

SellTue Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.62

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Peers